Journal
EXPERT REVIEW OF ANTICANCER THERAPY
Volume 15, Issue 4, Pages 433-438Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1586/14737140.2015.1003810
Keywords
inhibitor; pancreatic cancer; protein kinase C; therapy
Categories
Funding
- NIH [R01-CA140182]
Ask authors/readers for more resources
In preclinical studies, protein kinase C (PKC) enzymes have been implicated in regulating many aspects of pancreatic cancer development and progression. However, clinical Phase I or Phase II trials with compounds targeting classical PKC isoforms were not successful. Recent studies implicate that mainly atypical and novel PKC enzymes regulate oncogenic signaling pathways in pancreatic cancer. Members of these two subgroups converge signaling induced by mutant Kras, growth factors and inflammatory cytokines. Different approaches for the development of inhibitors for atypical PKC and novel PKC have been described; and new compounds include allosteric inhibitors and inhibitors that block ATP binding.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available